|本期目录/Table of Contents|

[1]管明秀,周云丽,王 萌,等.TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140-143.
 GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(02):140-143.
点击复制

TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
22卷
期数:
2016年02期
页码:
140-143
栏目:
临床医学
出版日期:
2016-03-20

文章信息/Info

Title:
Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area
文章编号:
1006-8147(2016)02-0140-04
作者:
管明秀12周云丽1王 萌1仝颖娜1刘晓彬1

(1.天津医科大学肿瘤医院检验科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津300060;2.天津市宝坻区人民医院检验科,天津医科大学宝坻临床学院,天津301800)

Author(s):
GUAN Ming-xiu12 ZHOU Yun-li1 WANG-Meng1TONG Ying-na1 LIU Xiao-bin1
(1.Department of Clinical Laboratory, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; 2.Department of Clinical Laboratory, Tianjin Baodi Hospital, Baodi Clinical College ,Tianjin Medical University, Tianjin 301800, China)
关键词:
前列腺癌前列腺特异性抗原丙酮酸激酶
Keywords:
prostatic cancer prostate specific antigen pyruvate kinase
分类号:
R737.25
DOI:
-
文献标志码:
A
摘要:
目的:比较TuM2-PK,tPSA,fPSA/tPSA和PSAD在PSA灰区对前列腺癌的诊断价值。方法:选取tPSA在4~10 ng/mL的前列腺癌(PCa)、良性前列腺癌增生(BPH)及前列腺炎老年患者共252例,测其血中TuM2-PK,tPSA和fPSA,计算fPSA/tPSA比值;经直肠B超测前列腺体积,计算tPSA与前列腺体积之比,得到PSAD。用SPSS19.0分析TuM2-PK,tPSA,fPSA/tPSA和PSAD在PSA灰区对PCa的诊断价值。结果:PCa组的TuM2-PK,fPSA/tPSA和PSAD较比前列腺炎老年组及BPH组均有显著变化(P<0.05);3组间的tPSA没有显著差异(P>0.05)。TuM2-PK AUC(0.948)>PSAD AUC(0.801)> fPSA/tPSA AUC (0.610)> tPSA AUC (0.499)。当TuM2-PK,tPSA,fPSA/tPSA和PSAD最佳临界值分别取24.30 U/mL、6.60 ng/mL、0.16和0.15 ng/mL/cm3时,诊断PCa的敏感性和特异性分别为88.9%和92.1%,72.2%和44.9%,80.5%和60.2%,83.3%和71.8%。结论:在PSA灰区,TuM2-PK、fPSA/tPSA、PSAD均能提高PCa诊断的敏感性和特异性,且TuM2-PK比fPSA/tPSA和PSAD对于PCa的诊断具有更高的准确性。
Abstract:

Objective: To explore diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for prostate cancer in PSA gray area. Methods: Two hundred and fifty-two cases with prostatic cancer (PCa), benign prostatic hyperplasia (BPH) and prostatitis whose tPSA levels were between 4 ng/mL and 10 ng/mL were chosen. Plasmatic TuM2-PK and serum fPSA, tPSA were examined. Prostate volume was determined by transrectal ultrasound. PSAD and fPSA/tPSA were calculated. The diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for PCa in PSA gray area were analyzed using SPSS19.0. Results: Compared with BPH group and elderly prostatitis group, TuM2-PK, fPSA/tPSA and PSAD in PCa group were significantly changed (P<0.05); There was no significant difference in tPSA among the three groups. The AUC of these indexes in descending order was TuM2-PK, PSAD, fPSA/tPSA, and tPSA. While the cutoffs of TuM2-PK, tPSA, fPSA/tPSA and PSAD were 24.30 U/mL, 6.60 ng/mL, 0.16 and 0.15 ng/mL/cm3, the sensitivity and specificity of diagnosed PCa were 88.9% and 92.1%,72.2% and 44.9%,80.5% and 60.2%,83.3% and 71.8%, respectively. Conclusion: TuM2-PK, fPSA/tPSA and PSAD can increase sensitivity and specificity inthediagnosis of PCa in PSA gray area. And compared with fPSA/tPSA and PSAD, TuM2-PK is more accurate in diagnosing PCa.

?

参考文献/References:

[1] 丁茗敏. 应用血清PSA进行前列腺癌筛查的意义[J]. 中国疗养医学, 2011,20(2):160

[2] Greene K L, Albertsen P C, Babaian R J, et al. Prostate specific antigen best practice statement: 2009 update[J]. J Urol, 2013,189(1 Suppl):S2

[3] 杨娜, 杨琳, 刘禄, 等. 探讨tPSA,fPSA,f/tPSA和PSAD对PSA灰区前列腺癌的诊断价值[J]. 临床医药实践, 2014,23(1):14

[4] Amirrasouli H, Kazerouni F, Sanadizade M, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population[J]. Urol J, 2010,7(2):99

[5] 范本, 齐范, 李文泽, 等. 湖南地区不同年龄、不同前列腺体积与血清中PSA及fPSA水平的相关性研究[J]. 实用预防医学, 2011,18(11):2034

[6] Li J, Yang Z, Zou Q, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer[J]. Clin Transl Oncol, 2014,16(2):200

[7] Fatela-Cantillo D, Fernandez-Suarez A, Moreno M A, et al. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients[J]. Tumour Biol, 2012,33(3):825

[8] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1):5

[9] Liu Z Y, Sun Y H, Xu C L, et al. Age-specific PSA reference ranges in Chinese men without prostate cancer[J]. Asian J Androl, 2009,11(1):100

[10] 马志远, 赵林海, 王阳, 等. PSA密度对TPSA灰区前列腺癌的诊断意义[J]. 临床泌尿外科杂志, 2011,26(2):132 .

[11] 贺乐乐, 魏伟, 杨进益. PSA及其相关指数对前列腺癌诊断价值的研究进展[J]. 现代泌尿生殖肿瘤杂志, 2015,7(3):190

[12] Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells[J]. Int J Biochem Cell Biol, 2011,43(7):969

[13] Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends Biochem Sci, 2012,37(8):309

[14] Morgan H P, O’Reilly F J, Wear M A, et al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation[J]. Proc Natl Acad Sci U S A, 2013,110(15):5881

[15] Gui D Y, Lewis C A, Vander H M . Allosteric regulation of PKM2 allows cellular adaptation to different physiological states[J]. Sci Signal, 2013,6(263):1290

[16] Gao X, Wang H, Yang J J, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012,45(5):598

[17] Feng C, Gao Y, Wang C, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2013,98(9):E1524

[18] 刘东林. 特拉唑嗪联合松花粉治疗慢性前列腺炎临床观察[J]. 山西医药杂志, 2014,43(19):2320

[19] Moller-Nielsen C, Sell A. Granulomatous prostatitis. Differential diagnosis from cancer of the prostate[J]. Ugeskr Laeger, 1983,145(13):994



?

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
 YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
 WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
 ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
 SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
 LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[8]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
 ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[9]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
 BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.
[10]徐庆祝,牛远杰.Gleason 10分前列腺癌患者临床特点分析[J].天津医科大学学报,2017,23(04):361.
 XU Qing-zhu,NIU Yuan-jie.Clinical and pathological research of prostate cancer with Gleason score 10[J].Journal of Tianjin Medical University,2017,23(02):361.

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目(81201653);天津市卫生局课题基金资助(2011KZ77)
作者简介 管明秀(1982-),女,临床检验初级技师,硕士在读,研究方向:临床检验诊断学;通信作者:周云丽,E-mail:zhouyunli@tjmuch.com

更新日期/Last Update: 2016-03-23